Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topaz Pharmaceuticals, a specialty pharmaceutical company, has named Bob Radie as president and CEO.
Subscribe to our email newsletter
Radie, most recently, served as president and CEO of TransMolecular, a biotechnology company developing new cancer diagnostic and treatment products.
Previously, Radie was chief business officer at Prestwick Pharmaceuticals and Morphotek.
Radie played leading roles in the acquisition of Prestwick by Biovail. in 2008 and Morphotek by Eisai in 2007 and also served as senior vice president of Strategic Projects and Planning at Vicuron Pharmaceuticals (acquired in 2005 by Pfizer).
Before joining Vicuron, Radie worked for Eli Lilly and Company, where he led several different sales forces and played a key role in numerous product launches.
Topaz Pharma’s lead product, Ivermectin topical cream, is concluding Phase 3 clinical trials to support a new drug application for the treatment of head lice.
Topaz Pharma non-executive chairman of the board Robert Casale said that Radie’s combination of business development experience as well as his expertise in successfully introducing new medicines into the commercial market is a great fit for Topaz as they prepare to report Phase 3 data on Ivermectin topical cream for the treatment of head lice.
"Bob’s extensive pharmaceutical experience should prove highly beneficial to Topaz as the company continues to advance this new product through the drug approval process," Casale said.
Radie said that he was honoured to join the team at Topaz as they advance a late-stage development product targeted for the treatment of head lice.
"I look forward to partnering with the team and Board of Directors as we propel Topaz to the next phase of commercial growth and optimising the value of the asset," Radie said.